Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

被引：1
|
作者：
Morris, Van K.
Yothers, Greg
Kopetz, Scott
Jacobs, Samuel A.
Lucas, Peter C.
Iqbal, Atif
Boland, Patrick M.
Deming, Dustin A.
Scott, Aaron James
Lim, Howard John
Wolmark, Norman
George, Thomas J.
机构：
[1] NRG Oncol, Houston, TX USA
[2] UT MD Anderson Canc Ctr, Houston, TX USA
[3] NRG Oncol, Pittsburgh, PA USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[7] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[8] Baylor Coll Med, Houston, TX 77030 USA
[9] Rutgers Canc Inst New Jersey & Alliance, New Brunswich, NJ USA
[10] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[11] ECOG ACRIN, Madison, WI USA
[12] Univ Arizona, Ctr Canc, Tucson, AZ USA
[13] SWOG, Tucson, AZ USA
[14] British Columbia Canc Vancouver, Vancouver, BC, Canada
[15] CCTG Cochair, Vancouver, BC, Canada
[16] NRG Oncol, Gainesville, FL USA
[17] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4121
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Puhalla, Shannon L.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Hong, Theodore S.
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Jacobs, Samuel A.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Jacobs, Samuel A.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Hong, Theodore S.
    Wolmark, Norman
    Georgenrg, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Jacobs, Samuel A.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Jacobs, Samuel A.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick Mckay
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Jacobs, Samuel A.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron James
    Lim, Howard John
    Hong, Theodore S.
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS259 - TPS259
  • [7] Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study.
    Morris, Van K.
    Yothers, Greg
    Kopetz, Scott
    Puhalla, Shannon L.
    Lucas, Peter C.
    Iqbal, Atif
    Boland, Patrick M.
    Deming, Dustin A.
    Scott, Aaron J.
    Lim, Howard J.
    Jacobs, Samuel A.
    Hong, Theodore S.
    Wolmark, Norman
    George, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 5 - 5
  • [8] Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA)
    Emily A. Verbus
    Alexander J. Rossi
    Allen J. Luna
    Atif Iqbal
    Van K. Morris
    Jonathan M. Hernandez
    Annals of Surgical Oncology, 2021, 28 : 4095 - 4097
  • [9] Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA)
    Verbus, Emily A.
    Rossi, Alexander J.
    Luna, Allen J.
    Iqbal, Atif
    Morris, Van K.
    Hernandez, Jonathan M.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) : 4095 - 4097
  • [10] Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer
    Akagunduz, Baran
    Guven, Deniz Can
    Ozer, Muhammet
    Okten, Ilker Nihat
    Atag, Elif
    Unek, Ilkay Tugba
    Tatli, Ali Murat
    Karaoglu, Aziz
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (02)
12345